Boothbay Fund Management’s Heron Therapeutics HRTX Stock Holding History

Boothbay Fund Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-32,324	Closed	-$185K	–	2427
2022 Q1	$185K	Buy	32,324 +3,864	+14%	+$28.3K	﹤0.01%	1910
2021 Q4	$260K	Sell	28,460 -9,368	-25%	-$95.6K	0.01%	1331
2021 Q3	$404K	Buy	37,828 +27,510	+267%	+$335K	0.01%	1185
2021 Q2	$160K	Buy	+10,318	New	+$164K	0.01%	1594
2020 Q2	–	Sell	-13,200	Closed	-$155K	–	1031
2020 Q1	$155K	Buy	+13,200	New	+$248K	0.01%	688
2015 Q4	–	Sell	-10,854	Closed	-$265K	–	609
2015 Q3	$265K	Buy	+10,854	New	+$362K	0.13%	227

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boothbay Fund Management's HRTX Position: Q2 2022 in Review

Boothbay Fund Management sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 32,324 shares — an estimated $185K sold.

Boothbay Fund Management first reported a position in HRTX in Q3 2015 and held it in 6 quarters. The position peaked at $404K in Q3 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

Boothbay Fund Management reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
Boothbay Fund Management sold 32,324 Heron Therapeutics shares in Q2 2022, an estimated $185K.
Boothbay Fund Management first reported a position in Heron Therapeutics in Q3 2015 and held it in 6 quarters.
Boothbay Fund Management's Heron Therapeutics position peaked at $404K in Q3 2021.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.